
Please try another search
Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has collaboration agreement with Affilogic, ENA Respiratory Pty Ltd, Lonza, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash University. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Mats Johansson | 63 | 2013 | Director |
Berndt Axelsson | 65 | 2013 | Independent Director |
Orest Lastow | 61 | 2013 | Co-Founder, Senior Scientific Advisor & Director |
Christer Fahraeus | 60 | 2025 | Independent Director |
Lennart Holm | 65 | - | Member of Business Advisory Board |
Carl Lindgren | 57 | 2023 | Independent Chairman |
Andreas Engstrom | 52 | 2025 | Independent Director |
Kjell Larsson | - | - | Member of Scientific Advisory Board |
Rikard Roos | 51 | - | Member of Business Advisory Board |
Björn Andersson | - | - | Member of Business Advisory Board |
Erik Westlund | 47 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review